| 1 | Chromothripsis-Mediated Small Cell Lung Carcinoma | 25.6 | 34 | Citations (PDF) |
| 2 | The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance | 26.1 | 67 | Citations (PDF) |
| 3 | Somatic estrogen receptor α mutations that induce dimerization promote receptor activity and breast cancer proliferation | 10.7 | 21 | Citations (PDF) |
| 4 | Image‐based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer | 5.0 | 14 | Citations (PDF) |
| 5 | Regression-based Deep-Learning predicts molecular biomarkers from pathology slides | 13.9 | 74 | Citations (PDF) |
| 6 | Converging and evolving immuno-genomic routes toward immune escape in breast cancer | 13.9 | 12 | Citations (PDF) |
| 7 | A Genomics-Driven Artificial Intelligence<b>–</b>Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers <i>CDH1</i> Inactivating Mechanisms | 0.6 | 17 | Citations (PDF) |
| 8 | Genotype-Directed Synthetic Cytotoxicity of ATR Inhibition with Radiotherapy | 6.9 | 4 | Citations (PDF) |
| 9 | High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer | 6.9 | 44 | Citations (PDF) |
| 10 | Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer | 25.6 | 108 | Citations (PDF) |
| 11 | Expanded genetic testing of GIST patients identifies high proportion of non-syndromic patients with germline alterations | 6.7 | 48 | Citations (PDF) |
| 12 | Biological insights and novel biomarker discovery through deep learning approaches in breast cancer histopathology | 6.5 | 47 | Citations (PDF) |
| 13 | Overcoming the challenges to implementation of artificial intelligence in pathology | 4.7 | 54 | Citations (PDF) |
| 14 | Dramatic, durable response to therapy in gBRCA2-mutated pancreas neuroendocrine carcinoma: opportunity and challenge | 6.7 | 6 | Citations (PDF) |
| 15 | A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer | 6.9 | 10 | Citations (PDF) |
| 16 | Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results | 39.5 | 81 | Citations (PDF) |
| 17 | Rare subtypes of triple negative breast cancer: Current understanding and future directions | 6.5 | 45 | Citations (PDF) |
| 18 | Clinicopathologic and genomic features of lobular like invasive mammary carcinoma: is it a distinct entity? | 6.5 | 12 | Citations (PDF) |
| 19 | Long-molecule scars of backup DNA repair in BRCA1- and BRCA2-deficient cancers | 38.7 | 33 | Citations (PDF) |
| 20 | Genomic analysis and clinical correlations of non-small cell lung cancer brain metastasis | 13.9 | 46 | Citations (PDF) |
| 21 | Non-cell-autonomous cancer progression from chromosomal instability | 38.7 | 225 | Citations (PDF) |
| 22 | Pitfalls in machine learning‐based assessment of tumor‐infiltrating lymphocytes in breast cancer: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer | 5.0 | 43 | Citations (PDF) |
| 23 | Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer | 5.0 | 37 | Citations (PDF) |
| 24 | Most large structural variants in cancer genomes can be detected without long reads | 26.1 | 32 | Citations (PDF) |
| 25 | Genomic characterization of small cell carcinomas of the uterine cervix | 4.2 | 31 | Citations (PDF) |
| 26 | Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130 | 4.7 | 77 | Citations (PDF) |
| 27 | Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome | 6.9 | 25 | Citations (PDF) |
| 28 | Pathogenesis of Triple-Negative Breast Cancer | 31.4 | 504 | Citations (PDF) |
| 29 | <i>ATM</i> Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications | 4.7 | 8 | Citations (PDF) |
| 30 | Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patientsCell, 2022, 185, 563-575.e11 | 34.1 | 524 | Citations (PDF) |
| 31 | Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression | 6.7 | 20 | Citations (PDF) |
| 32 | Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues | 3.1 | 12 | Citations (PDF) |
| 33 | Recurrent <i>WWTR1</i><scp>S89W</scp> mutations and Hippo pathway deregulation in clear cell carcinomas of the cervix | 5.0 | 7 | Citations (PDF) |
| 34 | LINC00355 regulates p27KIP expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer | 6.5 | 11 | Citations (PDF) |
| 35 | Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers | 6.5 | 23 | Citations (PDF) |
| 36 | Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer | 22.8 | 287 | Citations (PDF) |
| 37 | Microsatellite Instability–High Endometrial Cancers with <i>MLH1</i> Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles | 6.9 | 54 | Citations (PDF) |
| 38 | Solid-basaloid variant of adenoid cystic carcinoma of the breast with near complete response to neoadjuvant chemotherapy | 6.5 | 15 | Citations (PDF) |
| 39 | ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance | 6.5 | 23 | Citations (PDF) |
| 40 | Single-cell genomic variation induced by mutational processes in cancer | 38.7 | 122 | Citations (PDF) |
| 41 | Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer | 39.5 | 129 | Citations (PDF) |
| 42 | Pathogenic <i>ATM</i> Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy | 4.7 | 61 | Citations (PDF) |
| 43 | The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas | 4.2 | 35 | Citations (PDF) |
| 44 | Metaplastic carcinomas of the breast without evidence of epithelial differentiation: a diagnostic approach for management | 3.7 | 18 | Citations (PDF) |
| 45 | Ultraviolet radiation drives mutations in a subset of mucosal melanomas | 13.9 | 35 | Citations (PDF) |
| 46 | Homologous recombination deficiency: how genomic signatures are generated | 3.2 | 29 | Citations (PDF) |
| 47 | Genomic Alterations in <i>PIK3CA</i>-Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα Inhibitors | 0.6 | 34 | Citations (PDF) |
| 48 | Mesonephric and mesonephric-like carcinomas of the female genital tract: molecular characterization including cases with mixed histology and matched metastases | 4.9 | 106 | Citations (PDF) |
| 49 | Genomic profile of advanced breast cancer in circulating tumour DNA | 13.9 | 90 | Citations (PDF) |
| 50 | TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer | 6.5 | 26 | Citations (PDF) |
| 51 | Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development | 6.5 | 8 | Citations (PDF) |
| 52 | Genetic characterisation of adult primary pleomorphic uterine rhabdomyosarcoma and comparison with uterine carcinosarcoma | 3.7 | 6 | Citations (PDF) |
| 53 | Independent real‐world application of a clinical‐grade automated prostate cancer detection system | 5.0 | 152 | Citations (PDF) |
| 54 | Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer | 3.1 | 29 | Citations (PDF) |
| 55 | PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays | 3.6 | 12 | Citations (PDF) |
| 56 | Histologic and genomic features of breast cancers with alterations affecting the SWI/SNF (SMARC) genes | 4.9 | 8 | Citations (PDF) |
| 57 | Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma | 6.5 | 75 | Citations (PDF) |
| 58 | Paired Tumor-Normal Sequencing Provides Insights Into the <i>TP53</i>-Related Cancer Spectrum in Patients With Li-Fraumeni Syndrome | 4.7 | 15 | Citations (PDF) |
| 59 | Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies | 6.5 | 13 | Citations (PDF) |
| 60 | The clinical behavior and genomic features of the so-called adenoid cystic carcinomas of the solid variant with basaloid features | 4.9 | 43 | Citations (PDF) |
| 61 | Ki67 Assessment in Breast Cancer: Are We There Yet? | 4.7 | 10 | Citations (PDF) |
| 62 | Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination | 6.5 | 22 | Citations (PDF) |
| 63 | HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway | 13.9 | 76 | Citations (PDF) |
| 64 | Diverse alterations associated with resistance to KRAS(G12C) inhibition | 38.7 | 385 | Citations (PDF) |
| 65 | Pancreatoblastomas and mixed and pure acinar cell carcinomas share epigenetic signatures distinct from other neoplasms of the pancreas | 4.9 | 9 | Citations (PDF) |
| 66 | Immunohistochemical assessment of <i>HRAS</i> Q61R mutations in breast adenomyoepitheliomas | 3.7 | 29 | Citations (PDF) |
| 67 | Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary | 13.9 | 53 | Citations (PDF) |
| 68 | Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity | 4.9 | 58 | Citations (PDF) |
| 69 | Acquisition of APOBEC Mutagenesis and Microsatellite Instability Signatures in the Development of Brain Metastases in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma | 2.1 | 2 | Citations (PDF) |
| 70 | The genomic landscape of metastatic histologic special types of invasive breast cancer | 6.5 | 41 | Citations (PDF) |
| 71 | Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy | 22.8 | 174 | Citations (PDF) |
| 72 | FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer | 38.5 | 111 | Citations (PDF) |
| 73 | Histologic Classification and Molecular Signature of Polymorphous Adenocarcinoma (PAC) and Cribriform Adenocarcinoma of Salivary Gland (CASG) | 3.6 | 56 | Citations (PDF) |
| 74 | Unraveling tumor–immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy | 26.1 | 203 | Citations (PDF) |
| 75 | Oncogenic properties and signaling basis of the <scp><i>PAX8‐GLIS3</i></scp> fusion gene | 4.5 | 12 | Citations (PDF) |
| 76 | Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer | 6.5 | 165 | Citations (PDF) |
| 77 | Pleomorphic adenomas and mucoepidermoid carcinomas of the breast are underpinned by fusion genes | 6.5 | 37 | Citations (PDF) |
| 78 | Genomic profiling of primary and recurrent adult granulosa cell tumors of the ovary | 4.9 | 53 | Citations (PDF) |
| 79 | Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma | 4.9 | 31 | Citations (PDF) |
| 80 | ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer | 26.1 | 202 | Citations (PDF) |
| 81 | Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors | 22.8 | 140 | Citations (PDF) |
| 82 | Whole-Exome Sequencing Analysis of the Progression from Non–Low-Grade Ductal Carcinoma<i>In Situ</i>to Invasive Ductal Carcinoma | 6.9 | 66 | Citations (PDF) |
| 83 | Problematic breast tumors reassessed in light of novel molecular data | 4.9 | 35 | Citations (PDF) |
| 84 | Clonal relationship and directionality of progression of synchronous endometrial and ovarian carcinomas in patients with DNA mismatch repair-deficiency associated syndromes | 4.9 | 40 | Citations (PDF) |
| 85 | Homologous recombination DNA repair defects in PALB2-associated breast cancers | 6.5 | 49 | Citations (PDF) |
| 86 | How Did We Get There? The Progression from Ductal Carcinoma In Situ to Invasive Ductal Carcinoma | 0.8 | 2 | Citations (PDF) |
| 87 | PAX8–GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid | 4.9 | 54 | Citations (PDF) |
| 88 | Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas | 6.5 | 26 | Citations (PDF) |
| 89 | V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer | 25.6 | 43 | Citations (PDF) |
| 90 | Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential | 3.7 | 63 | Citations (PDF) |
| 91 | Genomic analysis of recurrences and high‐grade forms of polymorphous adenocarcinoma | 3.7 | 16 | Citations (PDF) |
| 92 | Solid pseudopapillary neoplasms of the pancreas are dependent on the Wnt pathway | 4.2 | 37 | Citations (PDF) |
| 93 | Massively parallel sequencing analysis of benign melanocytic naevi | 3.7 | 16 | Citations (PDF) |
| 94 | Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers | 3.5 | 39 | Citations (PDF) |
| 95 | Radiogenomics Analysis of Intratumor Heterogeneity in a Patient With High-Grade Serous Ovarian Cancer | 2.1 | 18 | Citations (PDF) |
| 96 | High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants | 39.5 | 630 | Citations (PDF) |
| 97 | Lobular Carcinomas <i>In Situ</i> Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma | 6.9 | 60 | Citations (PDF) |
| 98 | Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression | 3.1 | 88 | Citations (PDF) |
| 99 | Recurrent<i>MED12</i>exon 2 mutations in benign breast fibroepithelial lesions in adolescents and young adults | 2.0 | 26 | Citations (PDF) |
| 100 | The Genomic Landscape of Mucinous Breast Cancer | 4.7 | 80 | Citations (PDF) |
| 101 | Sclerosing epithelioid mesenchymal neoplasm of the pancreas – a proposed new entity | 4.9 | 14 | Citations (PDF) |
| 102 | Histologic spectrum of polymorphous adenocarcinoma of the salivary gland harbor genetic alterations affecting PRKD genes | 4.9 | 46 | Citations (PDF) |
| 103 | The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers | 4.7 | 113 | Citations (PDF) |
| 104 | Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases | 0.6 | 72 | Citations (PDF) |
| 105 | Invasion in breast lesions: the role of the epithelial–stroma barrier | 3.7 | 36 | Citations (PDF) |
| 106 | Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity | 6.4 | 86 | Citations (PDF) |
| 107 | Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway | 38.5 | 444 | Citations (PDF) |
| 108 | The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers | 38.5 | 863 | Citations (PDF) |
| 109 | Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors | 13.9 | 125 | Citations (PDF) |
| 110 | Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas | 13.9 | 122 | Citations (PDF) |
| 111 | Breast Cancer Heterogeneity: Roles in Tumorigenesis and Therapeutic Implications | 0.8 | 11 | Citations (PDF) |
| 112 | The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas | 6.9 | 150 | Citations (PDF) |
| 113 | Myxoid fibroadenomas differ from conventional fibroadenomas: a hypothesis‐generating study | 3.7 | 31 | Citations (PDF) |
| 114 | Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases | 6.9 | 103 | Citations (PDF) |
| 115 | Bi‐allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer | 5.0 | 55 | Citations (PDF) |
| 116 | Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes | 13.9 | 214 | Citations (PDF) |
| 117 | Phyllodes tumors with and without fibroadenoma-like areas display distinct genomic features and may evolve through distinct pathways | 6.5 | 66 | Citations (PDF) |
| 118 | The Spectrum of Triple-Negative Breast Disease | 3.4 | 172 | Citations (PDF) |
| 119 | An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer | 39.5 | 170 | Citations (PDF) |
| 120 | Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast | 6.5 | 79 | Citations (PDF) |
| 121 | Lack of <i><scp>PRKD</scp>2</i> and <i><scp>PRKD</scp>3</i> kinase domain somatic mutations in <i><scp>PRKD</scp>1</i> wild‐type classic polymorphous low‐grade adenocarcinomas of the salivary gland | 3.7 | 26 | Citations (PDF) |
| 122 | Infiltrating epitheliosis of the breast: characterization of histological features, immunophenotype and genomic profile | 3.7 | 38 | Citations (PDF) |
| 123 | Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and <i><scp>TERT</scp></i> promoter hotspot mutations and <i>TERT</i> gene amplification as likely drivers of progression | 5.0 | 127 | Citations (PDF) |
| 124 | Microglandular adenosis associated with triple‐negative breast cancer is a neoplastic lesion of triple‐negative phenotype harbouring <i><scp>TP53</scp></i> somatic mutations | 5.0 | 62 | Citations (PDF) |
| 125 | Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing | 3.7 | 24 | Citations (PDF) |
| 126 | <i>PALB2</i>,<i>CHEK2</i>and<i>ATM</i>rare variants and cancer risk: data from COGS | 3.9 | 204 | Citations (PDF) |
| 127 | Patient-derived xenograft (PDX) models in basic and translational breast cancer research | 7.2 | 243 | Citations (PDF) |
| 128 | Massively parallel sequencing analysis of synchronous fibroepithelial lesions supports the concept of progression from fibroadenoma to phyllodes tumor | 6.5 | 32 | Citations (PDF) |
| 129 | <i>IDH2</i> Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity | 0.6 | 121 | Citations (PDF) |
| 130 | Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology | 4.9 | 111 | Citations (PDF) |
| 131 | Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer | 6.9 | 190 | Citations (PDF) |
| 132 | Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer | 4.9 | 76 | Citations (PDF) |
| 133 | Phyllodes tumours of the breast: a consensus review | 3.7 | 432 | Citations (PDF) |
| 134 | Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants | 6.5 | 170 | Citations (PDF) |
| 135 | The Genomic Landscape of Male Breast Cancers | 6.9 | 136 | Citations (PDF) |
| 136 | Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family | 4.9 | 67 | Citations (PDF) |
| 137 | The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis‐generating study | 5.0 | 65 | Citations (PDF) |
| 138 | Are acinic cell carcinomas of the breast and salivary glands distinct diseases? | 3.7 | 50 | Citations (PDF) |
| 139 | <i>MED12</i> somatic mutations in fibroadenomas and phyllodes tumours of the breast | 3.7 | 91 | Citations (PDF) |
| 140 | Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas | 4.7 | 206 | Citations (PDF) |
| 141 | Breast Cancer Genomics From Microarrays to Massively Parallel Sequencing: Paradigms and New Insights | 4.7 | 84 | Citations (PDF) |
| 142 | Genomic landscape of adenoid cystic carcinoma of the breast | 5.0 | 150 | Citations (PDF) |
| 143 | Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification | 12.8 | 123 | Citations (PDF) |
| 144 | Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival | 2.4 | 89 | Citations (PDF) |
| 145 | PI3K Pathway Activation in High-Grade Ductal Carcinoma<i>In Situ</i>—Implications for Progression to Invasive Breast Carcinoma | 6.9 | 45 | Citations (PDF) |
| 146 | Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations | 8.2 | 129 | Citations (PDF) |
| 147 | Inference of Tumor Evolution during Chemotherapy by Computational Modeling and In Situ Analysis of Genetic and Phenotypic Cellular Diversity | 6.4 | 254 | Citations (PDF) |
| 148 | Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast | 5.0 | 95 | Citations (PDF) |
| 149 | Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands | 26.1 | 202 | Citations (PDF) |
| 150 | Metastatic breast carcinomas display genomic and transcriptomic heterogeneity | 4.9 | 92 | Citations (PDF) |
| 151 | Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple‐negative and basal‐like breast cancers | 5.0 | 158 | Citations (PDF) |
| 152 | Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis | 3.7 | 58 | Citations (PDF) |
| 153 | Gene expression profiling in breast cancer: classification, prognostication, and prediction | 52.8 | 674 | Citations (PDF) |
| 154 | Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas | 5.0 | 200 | Citations (PDF) |
| 155 | Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type | 5.0 | 153 | Citations (PDF) |
| 156 | Breast cancer precursors revisited: molecular features and progression pathways | 3.7 | 310 | Citations (PDF) |
| 157 | Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast | 4.9 | 61 | Citations (PDF) |
| 158 | Triple-Negative Breast Cancer | 43.7 | 3,774 | Citations (PDF) |
| 159 | Histological types of breast cancer: How special are they? | 4.2 | 469 | Citations (PDF) |
| 160 | Breast cancer molecular profiling with single sample predictors: a retrospective analysis | 26.0 | 339 | Citations (PDF) |
| 161 | Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice | 38.5 | 554 | Citations (PDF) |
| 162 | Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype? | 3.0 | 82 | Citations (PDF) |
| 163 | Microglandular adenosis or microglandular adenoma? A molecular genetic analysis of a case associated with atypia and invasive carcinoma | 3.7 | 51 | Citations (PDF) |
| 164 | Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type | 4.9 | 115 | Citations (PDF) |
| 165 | Histological and molecular types of breast cancer: is there a unifying taxonomy? | 75.5 | 387 | Citations (PDF) |
| 166 | Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis | 2.4 | 218 | Citations (PDF) |
